Immunovaccine Inc. Signs Collaboration Agreement with National Cancer Institute

HALIFAX, NOVA SCOTIA--(Marketwire - November 10, 2009) - Immunovaccine Inc. (TSX VENTURE: IMV), a vaccine development company, has signed a collaborative agreement with the National Cancer Institute (NCI) in Maryland, USA. The research collaboration involves formulating NCI’s cancer vaccine antigens in DepoVax™, Immunovaccine’s vaccine enhancement system.

“NCI is a world leader in the study of cancer biology and cancer therapy and we look forward to seeing how our enhanced DepoVax™ delivery system improves immune responses to treat cancer,” said Dr. Marc Mansour, vice president of R&D at Immunovaccine.

The research team at Immunovaccine will be collaborating with NCI investigator Dr. Jeffrey Schlom, head of the Immunotherapeutics group and chief of the Laboratory of Tumor Immunology & Biology. Dr. Schlom has significant ongoing research in the study of cancer vaccines and is well published in the design and characterization of recombinant vaccines for cancer therapy.

DepoVax™ is a vaccine enhancement and delivery platform which has demonstrated ability to enhance the immunogenicity of antigens by creating a strong “depot” at the site of immunization. Immunovaccine has previously shown eradication of tumors in three animal models with results published in peer reviewed journals. Immunovaccine has proven its scale-up capabilities at a contract manufacturing site with the ability to manufacture DepoVax™ - based vaccines for human clinical trials.

Immunovaccine Inc. (TSX VENTURE: IMV) is focused on the commercialization of its novel vaccine technology and product candidates. The company continues to strengthen its vaccine pipeline through licensing and strategic partnerships to develop therapeutic cancer and infectious disease vaccines. www.imvaccine.com

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future are forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.